Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal

Antiviral Research

Volumn 123, Issue , 2015, Pages 163-171

  Martínez Bonet, Marta ^a   Clemente, Maria Isabel ^a,b   Álvarez, Susana ^a   Díaz, Laura ^a,b   García Alonso, Dolores ^a   Muñoz, Eduardo ^c   Moreno, Santiago ^d   Muñoz Fernández, Maria Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Universidad de Cordoba   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Atripla; Bryostatin 1; HIV latency; HIV reactivation; Maraviroc

Indexed keywords

BRYOSTATIN 1; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MARAVIROC; ANTIRETROVIRUS AGENT; BRYOSTATIN; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; DRUG DETERMINATION; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS REACTIVATION; ADULT; CELL CULTURE; DRUG EFFECTS; DRUG INTERACTION; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VIROLOGY; VIRUS LATENCY;

ADULT; ANTI-RETROVIRAL AGENTS; BRYOSTATINS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYCLOHEXANES; DRUG INTERACTIONS; EFAVIRENZ, EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; HIV-1; HUMANS; MALE; MIDDLE AGED; TRIAZOLES; VIRUS LATENCY;

EID: 84946567572     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.09.014     Document Type: Article

References (50)

1. A. Alexaki, Y. Liu, and B. Wigdahl Cellular reservoirs of HIV-1 and their role in viral persistence Curr. HIV Res. 6 2008 388 400
2. H. Arberas, A.C. Guardo, M.E. Bargallo, M.J. Maleno, M. Calvo, J.L. Blanco, F. Garcia, J.M. Gatell, and M. Plana In vitro effects of the CCR5 inhibitor maraviroc on human T cell function J. Antimicrob. Chemother. 68 2013 577 586
3. N.M. Archin, A.L. Liberty, A.D. Kashuba, S.K. Choudhary, J.D. Kuruc, A.M. Crooks, D.C. Parker, E.M. Anderson, M.F. Kearney, M.C. Strain, D.D. Richman, M.G. Hudgens, R.J. Bosch, J.M. Coffin, J.J. Eron, D.J. Hazuda, and D.M. Margolis Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy Nature 487 2012 482 485
4. E.J. Beans, D. Fournogerakis, C. Gauntlett, L.V. Heumann, R. Kramer, M.D. Marsden, D. Murray, T.W. Chun, J.A. Zack, and P.A. Wender Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo Proc. Natl. Acad. Sci. U.S.A. 110 2013 11698 11703
5. L. Bousquet, A. Pruvost, A.C. Guyot, R. Farinotti, and A. Mabondzo Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation Antimicrob. Agents Chemother. 53 2009 896 902
6. C.K. Bullen, G.M. Laird, C.M. Durand, J.D. Siliciano, and R.F. Siliciano New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo Nat. Med. 20 2014 425 429
7. S.T. Butera, V.L. Perez, B.Y. Wu, G.J. Nabel, and T.M. Folks Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection J. Virol. 65 1991 4645 4653
8. M.J. Buzon, M. Massanella, J.M. Llibre, A. Esteve, V. Dahl, M.C. Puertas, J.M. Gatell, P. Domingo, R. Paredes, M. Sharkey, S. Palmer, M. Stevenson, B. Clotet, J. Blanco, and J. Martinez-Picado HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects Nat. Med. 16 2010 460 465
9. K.A. Clouse, D. Powell, I. Washington, G. Poli, K. Strebel, W. Farrar, P. Barstad, J. Kovacs, A.S. Fauci, and T.M. Folks Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone J. Immunol. 142 1989 431 438
10. T.W. Chun, J.S. Justement, D. Murray, C.W. Hallahan, J. Maenza, A.C. Collier, P.M. Sheth, R. Kaul, M. Ostrowski, S. Moir, C. Kovacs, and A.S. Fauci Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication AIDS 24 2010 2803 2808
11. T.W. Chun, D.C. Nickle, J.S. Justement, D. Large, A. Semerjian, M.E. Curlin, M.A. O'Shea, C.W. Hallahan, M. Daucher, D.J. Ward, S. Moir, J.I. Mullins, C. Kovacs, and A.S. Fauci HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir J. Clin. Invest. 115 2005 3250 3255
12. T.W. Chun, L. Stuyver, S.B. Mizell, L.A. Ehler, J.A. Mican, M. Baseler, A.L. Lloyd, M.A. Nowak, and A.S. Fauci Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc. Natl. Acad. Sci. U.S.A. 94 1997 13193 13197
13. G. del Real, S. Jimenez-Baranda, E. Mira, R.A. Lacalle, P. Lucas, C. Gomez-Mouton, M. Alegret, J.M. Pena, M. Rodriguez-Zapata, M. Alvarez-Mon, A.C. Martinez, and S. Manes Statins inhibit HIV-1 infection by down-regulating Rho activity J. Exp. Med. 200 2004 541 547
14. E.J. Duh, W.J. Maury, T.M. Folks, A.S. Fauci, and A.B. Rabson Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat Proc. Natl. Acad. Sci. U.S.A. 86 1989 5974 5978
15. T.M. Folks, K.A. Clouse, J. Justement, A. Rabson, E. Duh, J.H. Kehrl, and A.S. Fauci Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone Proc. Natl. Acad. Sci. U.S.A. 86 1989 2365 2368
16. T.M. Folks, J. Justement, A. Kinter, C.A. Dinarello, and A.S. Fauci Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line Science 238 1987 800 802
17. T.M. Folks, J. Justement, A. Kinter, S. Schnittman, J. Orenstein, G. Poli, and A.S. Fauci Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate J. Immunol. 140 1988 1117 1122
18. R.T. Gandhi, R.J. Bosch, E. Aga, M. Albrecht, L.M. Demeter, C. Dykes, B. Bastow, M. Para, J. Lai, R.F. Siliciano, J.D. Siliciano, and J.J. Eron No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy J. Infect. Dis. 201 2010 293 296
19. I. Garcia-Merino, N. de Las Cuevas, J.L. Jimenez, J. Gallego, C. Gomez, C. Prieto, M.J. Serramia, R. Lorente, and M.A. Munoz-Fernandez The Spanish HIV BioBank: a model of cooperative HIV research Retrovirology 6 2009 27
20. C. Gutierrez, L. Diaz, A. Vallejo, B. Hernandez-Novoa, M. Abad, N. Madrid, V. Dahl, R. Rubio, A.M. Moreno, F. Dronda, J.L. Casado, E. Navas, M.J. Perez-Elias, J. Zamora, S. Palmer, E. Munoz, M.A. Munoz-Fernandez, and S. Moreno Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected PLoS ONE 6 2011 e27864
21. D.H. Hamer, S. Bocklandt, L. McHugh, T.W. Chun, P.M. Blumberg, D.M. Sigano, and V.E. Marquez Rational design of drugs that induce human immunodeficiency virus replication J. Virol. 77 2003 10227 10236
22. D.V. Havlir, M.C. Strain, M. Clerici, C. Ignacio, D. Trabattoni, P. Ferrante, and J.K. Wong Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years J. Virol. 77 2003 11212 11219
23. K. Irie, R.C. Yanagita, and Y. Nakagawa Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cdelta Med. Res. Rev. 32 2012 518 535
24. B. Joos, M. Fischer, H. Kuster, S.K. Pillai, J.K. Wong, J. Boni, B. Hirschel, R. Weber, A. Trkola, and H.F. Gunthard HIV rebounds from latently infected cells, rather than from continuing low-level replication Proc. Natl. Acad. Sci. U.S.A. 105 2008 16725 16730
25. A. Jordan, D. Bisgrove, and E. Verdin HIV reproducibly establishes a latent infection after acute infection of T cells in vitro EMBO J. 22 2003 1868 1877
26. A. Jordan, P. Defechereux, and E. Verdin The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation EMBO J. 20 2001 1726 1738
27. C. Katlama, S.G. Deeks, B. Autran, J. Martinez-Picado, J. van Lunzen, C. Rouzioux, M. Miller, S. Vella, J.E. Schmitz, J. Ahlers, D.D. Richman, and R.P. Sekaly Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs Lancet 381 2013 2109 2117
28. T.L. Kieffer, M.M. Finucane, R.E. Nettles, T.C. Quinn, K.W. Broman, S.C. Ray, D. Persaud, and R.F. Siliciano Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads J. Infect. Dis. 189 2004 1452 1465
29. J. Kulkosky, and S. Bray HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication Curr. HIV Res. 4 2006 199 208
30. J. Kulkosky, D.M. Culnan, J. Roman, G. Dornadula, M. Schnell, M.R. Boyd, and R.J. Pomerantz Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART Blood 98 2001 3006 3015
31. A. Kumar, W. Abbas, and G. Herbein HIV-1 latency in monocytes/macrophages Viruses 6 2014 1837 1860
32. O. Kutsch, E.N. Benveniste, G.M. Shaw, and D.N. Levy Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency J. Virol. 76 2002 8776 8786
33. S. Madhusudan, A. Protheroe, D. Propper, C. Han, P. Corrie, H. Earl, B. Hancock, P. Vasey, A. Turner, F. Balkwill, S. Hoare, and A.L. Harris A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer Br. J. Cancer 89 2003 1418 1422
34. D. McMahon, J. Jones, A. Wiegand, S.J. Gange, M. Kearney, S. Palmer, S. McNulty, J.A. Metcalf, E. Acosta, C. Rehm, J.M. Coffin, J.W. Mellors, and F. Maldarelli Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy Clin. Infect. Dis. 50 2010 912 919
35. R. Mehla, S. Bivalkar-Mehla, R. Zhang, I. Handy, H. Albrecht, S. Giri, P. Nagarkatti, M. Nagarkatti, and A. Chauhan Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner PLoS One 5 2010 e11160
36. N. Madrid-Elena, B. Hernández-Novoa, B. Sastre-Turrión, S. Serrano-Villar, A. Solomon, C. Gutiérrez, J. Zamora, L. García-Bermejo, S. Lewin, and S. Moreno Maraviroc reverts latent HIV-1 in ART suppressed patients through NFκB without viral load increase IAS-USA/CROI 2014
37. M. Perez, A.G. de Vinuesa, G. Sanchez-Duffhues, N. Marquez, M.L. Bellido, M.A. Munoz-Fernandez, S. Moreno, T.P. Castor, M.A. Calzado, and E. Munoz Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency Curr. HIV Res. 8 2010 418 429
38. V.L. Perez, T. Rowe, J.S. Justement, S.T. Butera, C.H. June, and T.M. Folks An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation J. Immunol. 147 1991 3145 3148
39. S. Reuse, M. Calao, K. Kabeya, A. Guiguen, J.S. Gatot, V. Quivy, C. Vanhulle, A. Lamine, D. Vaira, D. Demonte, V. Martinelli, E. Veithen, T. Cherrier, V. Avettand, S. Poutrel, J. Piette, Y. de Launoit, M. Moutschen, A. Burny, C. Rouzioux, S. De Wit, G. Herbein, O. Rohr, Y. Collette, O. Lambotte, N. Clumeck, and C. Van Lint Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection PLoS One 4 2009 e6093
40. D. Sepulveda-Crespo, R. Lorente, M. Leal, R. Gomez, F.J. De la Mata, J.L. Jimenez, and M.A. Munoz-Fernandez Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide Nanomedicine 10 2014 609 618
41. M.E. Sharkey, I. Teo, T. Greenough, N. Sharova, K. Luzuriaga, J.L. Sullivan, R.P. Bucy, L.G. Kostrikis, A. Haase, C. Veryard, R.E. Davaro, S.H. Cheeseman, J.S. Daly, C. Bova, R.T. Ellison 3rd, B. Mady, K.K. Lai, G. Moyle, M. Nelson, B. Gazzard, S. Shaunak, and M. Stevenson Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy Nat. Med. 6 2000 76 81
42. L. Shen, and R.F. Siliciano Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection J. Allergy Clin. Immunol. 122 2008 22 28
43. K. Shirakawa, L. Chavez, S. Hakre, V. Calvanese, and E. Verdin Reactivation of latent HIV by histone deacetylase inhibitors Trends Microbiol. 21 2013 277 285
44. J.D. Siliciano, J. Lai, M. Callender, E. Pitt, H. Zhang, J.B. Margolick, J.E. Gallant, J. Cofrancesco Jr., R.D. Moore, S.J. Gange, and R.F. Siliciano Stability of the latent reservoir for HIV-1 in patients receiving valproic acid J. Infect. Dis. 195 2007 833 836
45. C.A. Spina, J. Anderson, N.M. Archin, A. Bosque, J. Chan, M. Famiglietti, W.C. Greene, A. Kashuba, S.R. Lewin, D.M. Margolis, M. Mau, D. Ruelas, S. Saleh, K. Shirakawa, R.F. Siliciano, A. Singhania, P.C. Soto, V.H. Terry, E. Verdin, C. Woelk, S. Wooden, S. Xing, and V. Planelles An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients PLoS Pathog. 9 2013 e1003834
46. A.M. Spivak, A. Andrade, E. Eisele, R. Hoh, P. Bacchetti, N.N. Bumpus, F. Emad, R. Buckheit 3rd, E.F. McCance-Katz, J. Lai, M. Kennedy, G. Chander, R.F. Siliciano, J.D. Siliciano, and S.G. Deeks A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy Clin. Infect. Dis. 58 2014 883 890
47. A. Vallejo, C. Gutierrez, B. Hernandez-Novoa, L. Diaz, N. Madrid, M. Abad-Fernandez, F. Dronda, M.J. Perez-Elias, J. Zamora, E. Munoz, M.A. Munoz-Fernandez, and S. Moreno The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients AIDS 26 2012 1885 1894
48. D. Warrilow, J. Gardner, G.A. Darnell, A. Suhrbier, and D. Harrich HIV type 1 inhibition by protein kinase C modulatory compounds AIDS Res. Hum. Retroviruses 22 2006 854 864
49. D.G. Wei, V. Chiang, E. Fyne, M. Balakrishnan, T. Barnes, M. Graupe, J. Hesselgesser, A. Irrinki, J.P. Murry, G. Stepan, K.M. Stray, A. Tsai, H. Yu, J. Spindler, M. Kearney, C.A. Spina, D. McMahon, J. Lalezari, D. Sloan, J. Mellors, R. Geleziunas, and T. Cihlar Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing PLoS Pathog. 10 2014 e1004071
50. S. Xing, C.K. Bullen, N.S. Shroff, L. Shan, H.C. Yang, J.L. Manucci, S. Bhat, H. Zhang, J.B. Margolick, T.C. Quinn, D.M. Margolis, J.D. Siliciano, and R.F. Siliciano Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation J. Virol. 85 2011 6060 6064